According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other analysts have also recently weighed in on the stock. Barclays started coverage on shares of Kura Oncology in a research note on Monday, May 4th. They issued an “overweight” rating and a $24.00 price objective for the company. BidaskClub cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, May 5th. Deutsche Bank reduced their price objective on shares of Kura Oncology from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday. Oppenheimer dropped their target price on shares of Kura Oncology from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Finally, Wedbush dropped their target price on shares of Kura Oncology from $30.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 6th. One analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Kura Oncology currently has a consensus rating of “Buy” and an average target price of $24.30.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.42) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.42). As a group, equities analysts anticipate that Kura Oncology will post -1.84 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in KURA. Group One Trading L.P. bought a new stake in Kura Oncology in the 4th quarter valued at $35,000. FDx Advisors Inc. bought a new stake in Kura Oncology in the 1st quarter valued at $37,000. KBC Group NV increased its holdings in Kura Oncology by 104.2% in the 4th quarter. KBC Group NV now owns 4,850 shares of the company’s stock valued at $67,000 after buying an additional 2,475 shares during the period. Bank of Montreal Can increased its holdings in Kura Oncology by 60.7% in the 4th quarter. Bank of Montreal Can now owns 4,838 shares of the company’s stock valued at $67,000 after buying an additional 1,828 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in Kura Oncology by 355.7% in the 1st quarter. Acadian Asset Management LLC now owns 7,693 shares of the company’s stock valued at $77,000 after buying an additional 6,005 shares during the period. 86.28% of the stock is currently owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.